CTOs on the Move

Signature Family Wealth

www.signaturefamilywealth.com

 
Signature is a Virginia-based multi-family office, offering clients comprehensive strategies and solutions for all aspects of their financial life. With assets under management in excess of $3.7 billion, Signature takes an intelligent approach to creating customized plans for their high net worth individuals and families.
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Decatur Vein Clinic

Decatur Vein Clinic is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Greer Laboratories

Greer Laboratories Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Greer Laboratories Inc. is based in Lenoir, NC. You can find more information on Greer Laboratories Inc. at www.greerlabs.com

Virtual Radiologic Corporation

Virtual Radiologic Corporation is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Virtual Radiologic Corporation is based in Eden Prairie, MN. You can find more information on Virtual Radiologic Corporation at www.virtualrad.com

CompManagement Health Systems

CompManagement Health Systems, Inc. is a Dublin, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.